Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Aixia Zhang; Xin Wang; Jianying Li; Lin Jing; Xiaodong Hu; Hejun Li; Chunxia Yang; Kerang Zhang; Ning Sun

doi:10.3389/fnins.2022.831278

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Front Neurosci. 2022 Feb 16:16:831278. doi: 10.3389/fnins.2022.831278. eCollection 2022.

Authors

Aixia Zhang^{1

2}, Xin Wang^{1

2}, Jianying Li^{1

2}, Lin Jing^{1

2}, Xiaodong Hu^{1

2}, Hejun Li^{1

2}, Chunxia Yang^{1

2}, Kerang Zhang^{1

2}, Ning Sun^{1

2

3}

Affiliations

¹ Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
² First Clinical Medical College of Shanxi Medical University, Taiyuan, China.
³ Department of Mental Health, Shanxi Medical University, Taiyuan, China.

Abstract

Objective: For major depressive disorder (MDD), there has been a lack of neuroimaging markers of efficacy of pharmacological treatment. In this study, we aimed to explore the neuroimaging mechanisms in patients with first-episode MDD and identify markers that predict the efficacy of 5-hydroxytryptamine reuptake inhibitors (SSRIs) with the use of resting-state brain imaging technology.

Methods: A total of 101 patients with first-episode MDD and 53 normal controls were finally included in this study. Based on the reduction rate of the score of Hamilton Depression Rating Scale (HAMD-17) during the 2-week SSRI treatment, 31 patients were assigned into the unresponsive group and 32 were assigned into the responsive group. The brain function was compared between patients with MDD and normal controls, and the diagnostic value of brain function was analyzed. With brain regions showing differences between patients with MDD and normal controls as a mask, and the brain function between the responsive and unresponsive groups were compared. Correlations between brain function the HAMD-17 score reduction rate during the 2-week SSRI treatment were analyzed.

Results: Compared to normal controls, patients with MDD showed increased ReHo in the left parahippocampal gyrus and right parahippocampal gyrus, decreased ReHo in the right middle occipital gyrus, and decreased functional connectivity between the right and left parahippocampal gyri, right middle occipital gyrus and middle temporal gyrus. Receiver operator characteristic (ROC) curve analysis showed that the area under the curve (AUC) was 0.544 (95% CI: 0.445-0.644) for ReHo and 0.822 (95% CI: 0.734-0.909) for functional connectivity. Logistic regression pooling of the differences in ReHo mean time series with the functional connectivity mean time series was performed for the ROC curve analysis, which showed an AUC of 0.832 (95% CI: 0.752-0.911). Compared to the responsive group, the unresponsive group showed elevated ReHo in the right parahippocampal gyrus and lower functional connectivity in the middle temporal gyrus. We also found that the ReHo value was negatively correlated with the HAMD-17 score reduction after 2 weeks of SSRI treatment.

Conclusion: Altered resting-state brain function in some regions might be a neurobiological marker for the diagnosis of MDD, and ReHo values are expected to be predictors of patient response to treatment with SSRIs.

Clinical trial registration: [http://www.chictr.org.cn/], identifier [ChiCTR1900028722].

Keywords: SSRIs; functional connectivity; major depressive disorder; regional homogeneity; resting-state functional MRI.